1.. INTRODUCTION
================

The multicentre phase [iii]{.smallcaps} randomized Breast Cancer International Research Group ([bcirg]{.smallcaps}) 001 trial ("[tac]{.smallcaps}--[fac]{.smallcaps}") showed that efficacy with docetaxel (Taxotere: Sanofi--Aventis, Laval, QC) in combination with doxorubicin and cyclophosphamide ([tac]{.smallcaps} protocol) was improved over that with the standard protocol of 5-fluorouracil, doxorubicin, cyclophosphamide ([fac]{.smallcaps}) for the adjuvant treatment of patients with operable node-positive breast cancer. The study observed 1491 women between the ages of 18 and 70 years with axillary node--positive breast cancer who were randomly assigned to 6 cycles of either [tac]{.smallcaps} or [fac]{.smallcaps} as adjuvant chemotherapy after surgery. Administration of granulocyte colony--stimulating factor ([g]{.smallcaps}-[csf]{.smallcaps}) was given to only patients who experienced 1 episode of febrile neutropenia or infection.

As compared with [fac]{.smallcaps}, the [tac]{.smallcaps} regimen was associated with a higher incidence of febrile neutropenia, but this higher incidence did not result in a significantly different or elevated rate of moderate-to-severe infection in the patients who received [tac]{.smallcaps} chemotherapy. During a 5-year follow-up period, the study showed improved disease-free survival ([dfs]{.smallcaps}, primary efficacy endpoint) and overall survival ([os]{.smallcaps}, secondary endpoint) for patients receiving the [tac]{.smallcaps} protocol as compared with those receiving the [fac]{.smallcaps} protocol [@b1-conc17-1-7]. The expansion of the indication for [tac]{.smallcaps} from advanced to early breast cancer may lead to an increase in chemotherapy expenditures for hospitals and provincial payers alike. However, recurrences avoided by the use of [tac]{.smallcaps} will have an effect in terms of years of life saved and may generate cost savings attributable to the reduction in disease recurrence.

2.. OBJECTIVE
=============

The objective of the present economic analysis was to compare, from the perspective of Cancer Care Ontario ([cco]{.smallcaps}) and the Ontario Ministry of Health and Long-Term Care, the effectiveness, cost, and incremental cost-effectiveness of two adjuvant chemotherapy strategies after primary surgery for breast cancer in women with operable, axillary lymph node--positive breast cancer:

-   **[tac]{.smallcaps}** Docetaxel 75 mg/m^2^ as a 1-hour intravenous (IV) infusion, in combination with doxorubicin 50 mg/m^2^ as an IV infusion and cyclophosphamide 500 mg/m^2^ as an IV infusion, all given on day 1 every 3 weeks for 6 cycles.

-   **[fac]{.smallcaps}** 5-Fluorouracil 500 mg/m^2^ as an IV infusion, in combination with doxorubicin 50 mg/m^2^ as an IV infusion and cyclophosphamide 500 mg/m^2^ as an IV infusion, all given on day 1 every 3 weeks for 6 cycles.

3.. METHODS
===========

The [tac]{.smallcaps}--[fac]{.smallcaps} study showed that 6 cycles of the [tac]{.smallcaps} protocol were superior to 6 cycles of the [fac]{.smallcaps} protocol with respect to [dfs]{.smallcaps} and [os]{.smallcaps} in a group of patients with node-positive breast cancer over a 5-year time horizon [@b1-conc17-1-7]. The cost of [tac]{.smallcaps} is greater than the cost of [fac]{.smallcaps} when it comes to acquisition, administration, and adverse event management. Given the superior efficacy but higher cost of [tac]{.smallcaps}, a cost-effectiveness analysis was considered a reasonable economic evaluation [@b2-conc17-1-7]. An incremental cost per life-year ([ly]{.smallcaps}) gained was the primary economic outcome. A secondary economic outcome was the incremental cost per quality-adjusted life-year ([qaly]{.smallcaps}) gained.

A Markov model ([Figure 1](#f1-conc17-1-7){ref-type="fig"}), developed from the perspective of [cco]{.smallcaps} and the Ontario Ministry of Health and Long-Term Care, was used to follow a population of patients treated in the [tac]{.smallcaps}--[fac]{.smallcaps} study \[1480 subjects, 99.3% of the overall population; 744 in the [tac]{.smallcaps} arm (99.9%), 736 in the [fac]{.smallcaps} arm (98.7%); median age: 49.0 years\]. Patients in the [tac]{.smallcaps} arm experienced 141 recurrences (19.0%) and 162 deaths (21.8%); in the [fac]{.smallcaps} arm, the numbers were 195 (26.5%) and 246 (33.4%) respectively [@b3-conc17-1-7],[@b4-conc17-1-7]. A cycle length of 6 months was used. The decision--analytic model started at the initiation of adjuvant chemotherapy. The model measured disease recurrences within the remaining years of life for all patients, and it comprises these health states:

-   ***No Recurrence:*** No disease progression

-   ***Locoregional Recurrence:*** Recurrence without metastases

-   ***Distant (Metastatic) Recurrence:*** Recurrence with metastases

-   ***Deceased:*** Patient died (from breast cancer cause or other causes)

"Deceased" is an "absorbing state." Any given woman could stay in the other three "non-absorbing" health states for more than one Markov cycle.

All women start in the No Recurrence state. Any given women could stay at the same state for more than one cycle or progress into the next state, with the final state being Deceased ([Figure 1](#f1-conc17-1-7){ref-type="fig"}). The lifetime horizon included two time periods, a period of treatment and observation (5 years, corresponding to the length of the [tac]{.smallcaps}--[fac]{.smallcaps} study) and a period of follow-up for surviving patients (beyond the 5th year until death).

The construct of this model makes certain assumptions. Recurrences (at 5 years) are considered mutually exclusive: patients could have either a Locoregional or Distant (Metastatic) recurrence. Death can occur after the No Recurrence, Locoregional Recurrence, or Distant (Metastatic) Recurrence states. In the base-case analysis, the assumption was made that filgrastim ([g]{.smallcaps}-[csf]{.smallcaps}) was given secondary to an episode of febrile neutropenia per the [tac]{.smallcaps}--[fac]{.smallcaps} study protocol, and a standard weight was used for patients. Transfusion rates were based on the percentage of patients that had a "need for blood transfusions" as reported in the [tac]{.smallcaps}--[fac]{.smallcaps} study [@b1-conc17-1-7]. The base-case analysis comparing [tac]{.smallcaps} with [fac]{.smallcaps} was constructed using the entire population of the [tac]{.smallcaps}--[fac]{.smallcaps} study and [g]{.smallcaps}-[csf]{.smallcaps} as secondary prophylaxis for febrile neutropenia over a lifetime time horizon.

Two measures of effectiveness (outcome) were considered in the analysis: [ly]{.smallcaps}s gained (based on study [dfs]{.smallcaps}) and [qaly]{.smallcaps}s gained. Grade 3 or 4 serious adverse events of febrile neutropenia, stomatitis, diarrhea, and infection [@b1-conc17-1-7] were included. Results at 5 years from the [tac]{.smallcaps}--[fac]{.smallcaps} study were used to derive the 6-month constant probabilities of Locoregional Recurrence and Distant (Metastatic) Recurrence, and the 6-month constant probabilities of Death for patients coming from any previous state \[No Recurrence, Locoregional Recurrence, and Distant (Metastatic) Recurrence\].

Health utilities were not collected during the [tac]{.smallcaps}--[fac]{.smallcaps} study, and we therefore obtained sources in the literature [@b5-conc17-1-7]--[@b7-conc17-1-7]. The disutility associated with the use of docetaxel in the [tac]{.smallcaps} arm was based on the disutility associated with adverse events in patients who had received docetaxel in the [tac]{.smallcaps}--[fac]{.smallcaps} study, the probability of an adverse event, the number of adverse events, and the duration of adverse events in that study [@b1-conc17-1-7],[@b3-conc17-1-7]. The disutility associated with adverse events was calculated to be 0.0072 for the [tac]{.smallcaps} regimen and was found to be 0.0035 [@b8-conc17-1-7] for the [fac]{.smallcaps} regimen, for a difference of 0.0037. In the base case, the utility value for the [fac]{.smallcaps} regimen was assumed to 0.72 (reflecting utility values for adjuvant chemotherapy [@b9-conc17-1-7]) and the utility value for the [tac]{.smallcaps} regimen was calculated to 0.7163 (based on the utility value for [fac]{.smallcaps}, less the incremental disutilities attributable to the adverse events: 0.72 -- 0.0037). Utility values for health states were the same for both groups. For No Recurrence, Locoregional Recurrence, and Distant (Metastatic) Recurrence, utility values were 0.960 [@b5-conc17-1-7], 0.816 [@b5-conc17-1-7], and 0.49--0.65 [@b6-conc17-1-7] (mean: 0.57) [@b7-conc17-1-7] respectively.

3.1. Costs
----------

Model costs included direct medical costs---namely, drug acquisition costs for the [tac]{.smallcaps} and [fac]{.smallcaps} treatments; adverse events costs for grades 3 and 4 febrile neutropenia, stomatitis, diarrhea, and infection; and costs of primary and secondary prophylaxis with [g]{.smallcaps}-[csf]{.smallcaps}. Infusion times for drug administration were considered in the calculation of drug costs. Costs associated with chemotherapy administration, with follow-up, and with Distant (Metastatic) and Locoregional recurrence chemotherapy regimens, supportive care, and diagnostic tests were also considered.

Costs of the assessed treatments included drug acquisition and administration costs, which include 2.5 hours of chair time for [tac]{.smallcaps} and 1.5 hours of chair time for [fac]{.smallcaps}, with nursing and overhead, for the 6 cycles of treatment. These costs were applied once in the model at the starting point (time 0). Drug acquisition costs were obtained from [cco]{.smallcaps} and Sanofi--Aventis Canada.

The model uses 2006 Canadian costs. All non--2006 costs were inflated to 2006 Canadian dollars. Costs and outcomes were discounted at a rate of 5% [@b2-conc17-1-7]. Nonmedical and indirect costs were not considered in the analysis, per the provincial ministry of health perspective. The cost of capital equipment was not included in this analysis. The equipment to administer [tac]{.smallcaps} was assumed to exist in a hospital setting established to administer chemotherapy.

### 3.1.1. Costs of Chemotherapies for Subsequent Metastatic Disease

After the administration of adjuvant chemotherapy, the costs of subsequent chemotherapy for patients in the metastatic setting were based on advanced breast cancer treatment protocols from the [cco]{.smallcaps} Drug Formulary [@b10-conc17-1-7]. The cost of a treatment comprises drug acquisition costs and chemotherapy administration time. The protocol was multiplied by its percent utilization, and protocols were then stratified into first-line, second-line, and third-line chemotherapy regimens based on [cco]{.smallcaps} practice guidelines [@b10-conc17-1-7]. It was assumed that the costs for fourth- and fifth-line chemotherapy would be the same as for third-line chemotherapy. [Table I](#tI-conc17-1-7){ref-type="table"} details the specific regimens given as subsequent lines of therapy in the [fac]{.smallcaps} and [tac]{.smallcaps} groups. In the [tac]{.smallcaps} arm, in the first line, trastuzumab and vinorelbine were given to patients positive for the human epidermal growth factor receptor ([her]{.smallcaps}2+), and capecitabine or vinorelbine were given to patients negative for the receptor ([her]{.smallcaps}2−). In the [fac]{.smallcaps} arm, in the first line, trastuzumab and docetaxel were given to [her]{.smallcaps}2+ patients, and docetaxel was given to [her]{.smallcaps}2− patients. In the second line, [her]{.smallcaps}2+ and [her]{.smallcaps}2− patients in both arms were given capecitabine. In the [tac]{.smallcaps} arm, [her]{.smallcaps}2− patients could receive vinorelbine instead of capecitabine. In the third line, docetaxel was given to [her]{.smallcaps}2+ patients in the [tac]{.smallcaps} arm, and vinorelbine was given to [her]{.smallcaps}2+ patients in the [fac]{.smallcaps} arm.

### 3.1.2. Costs of Supportive Care

In the model, supportive care costs consisted only of concomitant medications used in the administration of chemotherapy ([Table I](#tI-conc17-1-7){ref-type="table"}). Costs for transfusions were determined by multiplying the proportion of patients described as having had a "need for a blood transfusion" per the [tac]{.smallcaps}--[fac]{.smallcaps} study results by the cost of the transfusion. All patients received ondansetron for nausea and dexamethasone; the average cost of ondansetron and dexamethasone per patient was calculated (Trudeau M. Personal communication). The final average supportive care cost per patient entered into the model was \$65.08.

### 3.1.3. Costs of Adverse Events

With respect to adverse events, only grade 3 or 4 events with statistically significant differences between the two evaluated regimens and potentially leading to hospitalization were considered in the model. The adverse events considered were febrile neutropenia, stomatitis, diarrhea, and infection ([Table II](#tII-conc17-1-7){ref-type="table"}). All other adverse events reported (for example, anemia, thrombocytopenia, asthenia, vomiting and nausea, abdominal pain, and so on) were assumed to have a marginal effect on the economic outcomes, because they were not statistically different between the two groups [@b1-conc17-1-7]. The model assumed that the adverse events were considered to be directly associated with the [tac]{.smallcaps} and [fac]{.smallcaps} chemotherapies and to occur over the treatment period, per the results of the [tac]{.smallcaps}--[fac]{.smallcaps} study. Codes from the *International Statistical Classification of Diseases and Related Health Problems,* 10th revision, for febrile neutropenia, stomatitis, diarrhea and infection were determined and costed using the Ontario Case Costing Initiative [@b13-conc17-1-7]. These costs were applied once in the model at the starting point (time 0, corresponding to the advanced treatment phase). The cost of febrile neutropenia included hospitalization costs and treatment of febrile neutropenia with [g]{.smallcaps}-[csf]{.smallcaps}. Per the [tac]{.smallcaps}--[fac]{.smallcaps} study, all patients received prophylactic antibiotics [@b1-conc17-1-7] at a cost of \$314.10. An average adverse event cost per patient was calculated based on the percentage occurrence of each adverse event multiplied by the cost per event. Diagnostic and procedural costs associated with the treatment of breast cancer are listed in [Table I](#tI-conc17-1-7){ref-type="table"}.

### 3.1.4. Follow-Up Costs

Information on follow-up procedures and the frequency of those procedures was validated by the clinical authors of this article. Associated costs were obtained from the Ontario Ministry of Health and Long-Term Care *Schedule of Benefits* [@b16-conc17-1-7]. Procedures included physician or oncologist visits, mammograms, laboratory testing, and radiology. Annual costs were determined by multiplying costs per episode by the annual frequency of the procedure, and a total annual cost of all follow-up procedures was obtained.

For women with Distant (Metastatic) Recurrence, the total annual cost of follow-up was determined to be \$1,729.10.

Follow-up costs for women without recurrence of breast cancer included physician assessments, clinical costs (including overhead), hematology, biochemistry, bone scan, chest radiographs, liver ultrasound, and annual mammogram [@b15-conc17-1-7]. The cost was stated as \$582.82 in year 1, declining to \$356.93 by year 5, after inflation. It was assumed that years 1--3 had a follow-up cost of \$582.82 and that all years thereafter had a cost of \$356.93.

Follow-up costs for women with Locoregional Recurrence were \$1,032.76 for years 1 and 2, \$764.27 for years 3 and 4, and \$620.65 for years 5 and beyond, after inflation. The annual cost was \$805.89, based on an average of 6 years ([Table I](#tI-conc17-1-7){ref-type="table"}).

### 3.1.5. Cost of Secondary Prophylaxis with G-CSF after a First Episode of Febrile Neutropenia

The average cost per patient for secondary prophylaxis with [g]{.smallcaps}-[csf]{.smallcaps} was determined by multiplying the cost per event by the proportion of patients who received any secondary prophylaxis by the average number of cycles for which they received secondary prophylaxis ([Table III](#tIII-conc17-1-7){ref-type="table"}). Detailed secondary prophylaxis information was not available from the publication. Here, the unpublished clinical study report was used to provide the data. The average cost per patient of secondary prophylaxis was considered only once for each arm of treatment at the starting point of the model (time 0, corresponding to the adjuvant treatment phase).

### 3.1.6. Cost of Primary Prophylaxis of Febrile Neutropenia with G-CSF

In the [tac]{.smallcaps}--[fac]{.smallcaps} study, patients who experienced febrile neutropenia received [g]{.smallcaps}-[csf]{.smallcaps} (secondary prophylaxis). We wanted to conduct an alternative analysis looking at the cost-effectiveness of [tac]{.smallcaps} versus [fac]{.smallcaps} in the context of primary [g]{.smallcaps}-[csf]{.smallcaps} prophylaxis---that is, the administration of [g]{.smallcaps}-[csf]{.smallcaps} before the occurrence of febrile neutropenia or other documented infection. To do so, we used the [geicam]{.smallcaps} (Grupo Español de Investigación del Cáncer de Mama) 9805 study [@b17-conc17-1-7] for the costing of adverse events, because we could then compare adverse events rates with and without primary prophylaxis within the context of a single study. Because the rate of febrile neutropenia in the [tac]{.smallcaps} group was the major driver of adverse event costs and the variable that would be affected by [g]{.smallcaps}-[csf]{.smallcaps} prophylaxis, it is important to note that the adverse event rates for grades 3 and 4 febrile neutropenia reported in the [geicam]{.smallcaps} study for the pre-[tac]{.smallcaps} and [fac]{.smallcaps} groups were similar to those reported in the [tac]{.smallcaps}--[fac]{.smallcaps} study [@b1-conc17-1-7]. In this scenario, as in our base-case analysis, all patients received antibiotic prophylaxis.

3.2. Sensitivity Analysis
-------------------------

Sensitivity analyses (one-way and bootstrapping) were conducted to test the robustness of results with regard to variations in key parameters considered in the model. Sensitivity analyses were conducted for adverse event rates, the rate of febrile neutropenia, the proportion of recurrences in the Locoregional and Distant (Metastatic) recurrence states, follow-up and supportive care costs, utility values, and transition probabilities. [Table IV](#tIV-conc17-1-7){ref-type="table"} outlines the specific analyses.

### 3.2.1. Analysis

An incremental cost-effectiveness analysis was conducted for the base-case analysis. A number of one-way and bootstrapping sensitivity analyses were conducted as described in the preceding subsection. Additionally, an alternative analysis using [g]{.smallcaps}-[csf]{.smallcaps} as primary prophylaxis was conducted, and sensitivity analyses were built around that model as well.

A number of assumptions were made in constructing this model:

-   Transition probabilities were constant over time. Because recurrence rates were available only at 5 years, 5-year rates were converted into 6-month probabilities such as the probability of any single patient having a recurrence in any given model cycle (semester). The formula for the time conversion is

    $$1 - \text{e}^{- \text{rate}*\text{time}}.$$

-   For instance, if 30% of women experienced a recurrence at 5 years (ten Markov cycles), the constant 6-month transition probability was

    $$0.029\,\lbrack 1 - \text{e}^{- 0.3*1/10}\rbrack$$

-   Recurrences were considered mutually exclusive (at 5 years). Patients could either have a Locoregional Recurrence or a Distant (Metastatic) Recurrence.

-   Death could occur after the No Recurrence, the Locoregional Recurrence, or the Distant (Metastatic) Recurrence states

-   In the base-case analysis, we assumed that the costs of fourth- and fifth-line chemotherapy regimens were identical to those of third-line chemotherapy.

-   In the base-case analysis, we assumed that filgrastim ([g]{.smallcaps}-[csf]{.smallcaps}) was given secondary to an episode of febrile neutropenia, per the [tac]{.smallcaps}--[fac]{.smallcaps} study.

-   A weight of 60 kg and 7 days of [g]{.smallcaps}-[csf]{.smallcaps} therapy per cycle were assumed for patients receiving [g]{.smallcaps}-[csf]{.smallcaps}.

-   Only grade 3 or 4 adverse events with statistically significant differences were considered in the analysis. These included febrile neutropenia, infection, stomatitis, and diarrhea ([Table V](#tV-conc17-1-7){ref-type="table"}).

-   For patients experiencing anemia, only needed blood transfusions were costed and included in the analysis.

At baseline, the median age of patients in the [tac]{.smallcaps}--[fac]{.smallcaps} study was 49 years. The duration of the study was 5 years. Life expectancy was extrapolated based on the Wisconsin population for a woman starting at 55 years of age [@b18-conc17-1-7], corresponding approximately to the mean age of the women completing the clinical trial. A life expectancy was assigned to each patient according to health status at the end of the [tac]{.smallcaps}--[fac]{.smallcaps} clinical trial time horizon. It should also be noted that the adverse event rates used in the primary [g]{.smallcaps}-[csf]{.smallcaps} prophylaxis sensitivity analysis were taken from the [geicam]{.smallcaps} study, because those rates provided information about adverse events after primary prophylaxis ([Table V](#tV-conc17-1-7){ref-type="table"}).

4.. RESULTS
===========

The base-case analysis used in this model applied a 5% discount rate, the Canadian costs for chemotherapies recommended by [cco]{.smallcaps} guidelines [@b10-conc17-1-7], and febrile neutropenia rates based on the available [tac]{.smallcaps}--[fac]{.smallcaps} study results [@b17-conc17-1-7]. The incremental cost-effectiveness ratio ([icer]{.smallcaps}) for [tac]{.smallcaps} compared with [fac]{.smallcaps} was \$6,921.24/[ly]{.smallcaps} gained. The incremental cost--utility ratio ([icur]{.smallcaps}) for [tac]{.smallcaps} compared with [fac]{.smallcaps} was \$6,848.39/[qaly]{.smallcaps} ([Table IV](#tIV-conc17-1-7){ref-type="table"}).

Several one-way and probabilistic sensitivity analyses were conducted. Adverse event rates used in the base-case model were altered in a variety of ways in the sensitivity analyses. When the rates were increased by 25%, the incremental ratios were \$7,129.14/[ly]{.smallcaps} gained and \$7,054.09/[qaly]{.smallcaps} gained. When decreased by 25%, the incremental ratios were \$6,713.35/[ly]{.smallcaps} gained and \$6,642.68/[qaly]{.smallcaps} gained. When adverse event rates were increased and decreased by 25% in the [tac]{.smallcaps} group only, the [icer]{.smallcaps}s were \$7,188.70/[ly]{.smallcaps} gained and \$6,653.78/[ly]{.smallcaps} gained for [tac]{.smallcaps} and [fac]{.smallcaps} respectively, and the [icur]{.smallcaps}s were \$7,113.03/[qaly]{.smallcaps} and \$6,583.74/[qaly]{.smallcaps} respectively. Febrile neutropenia rates were increased and decreased by 25%, giving incremental ratios of \$7,076.75/[ly]{.smallcaps} and \$7,002.26/[qaly]{.smallcaps} gained and \$6,765.73/[ly]{.smallcaps} and \$6,694.52/[qaly]{.smallcaps} gained for [tac]{.smallcaps} and [fac]{.smallcaps} respectively.

The bootstrapping sensitivity analysis examined a lower and an upper bound for the cost per [dfs]{.smallcaps}. The [icer]{.smallcaps}s ranged from \$3,132.16/[dfs]{.smallcaps} for the best-case scenario to \$20,370.59/[dfs]{.smallcaps} for the worst-case scenario. The [icur]{.smallcaps}s ranged from \$3,060.59/[qaly]{.smallcaps} for the best-case scenario to \$20,036.64/[qaly]{.smallcaps} for the worst-case scenario.

When the model was run using the adverse events observed in the [geicam]{.smallcaps} study, in which no primary [g]{.smallcaps}-[csf]{.smallcaps} prophylaxis was allowed, the [icer]{.smallcaps} was \$6,893.22/[ly]{.smallcaps} gained and the [icur]{.smallcaps} was \$6,820.66/[qaly]{.smallcaps} gained for [tac]{.smallcaps} compared with [fac]{.smallcaps}. The results of this analysis were very comparable to those based on the [tac]{.smallcaps}--[fac]{.smallcaps} study, which supports our rationale for using the adverse events rates in the [geicam]{.smallcaps} study to evaluate the effect of primary [g]{.smallcaps}-[csf]{.smallcaps} prophylaxis on the cost-effectiveness of the [tac]{.smallcaps} regimen. When [g]{.smallcaps}-[csf]{.smallcaps} was given as primary prophylaxis, the incremental costs were \$13,183.26/[ly]{.smallcaps} and \$13,044.49/[qaly]{.smallcaps} gained for [tac]{.smallcaps} compared with [fac]{.smallcaps}. The overall cost and the incremental benefit were both higher as compared with the base-case results when [g]{.smallcaps}-[csf]{.smallcaps} was given prophylactically before each cycle.

[Table IV](#tIV-conc17-1-7){ref-type="table"} also outlines additional sensitivity analyses (including relapse rate, follow-up costs, ratio of recurrence, and utility) and additional analyses with [g]{.smallcaps}-[csf]{.smallcaps} as a primary prophylaxis. Increases in the costs associated with follow-up of patients with No Recurrence are observed to result in increased [icer]{.smallcaps}s, whereas increases in the costs associated with follow-up of patients with Distance (Metastatic) Recurrence are observed to result in a decreased [icer]{.smallcaps}, but to a far lesser extent than the increase seen with No Recurrence.

5.. DISCUSSION
==============

Based on the literature, [tac]{.smallcaps} offers improved [dfs]{.smallcaps} compared with [fac]{.smallcaps}, at a higher cost [@b3-conc17-1-7]. Patients receiving [tac]{.smallcaps} had a 6-month greater life expectancy than did patients receiving [fac]{.smallcaps}. The incremental cost-effectiveness ratios for [tac]{.smallcaps} compared with [fac]{.smallcaps} (\$6,921.24/[ly]{.smallcaps} gained and \$6,848.39/[qaly]{.smallcaps} gained) indicate good economic value for [tac]{.smallcaps} treatment in the adjuvant setting of node-positive breast cancer patients. Life expectancies adjusted by utilities were lower than the unadjusted life expectancies, but the difference in [qaly]{.smallcaps}s gained between the two study groups was greater than the observed difference in [ly]{.smallcaps}s gained, explaining why the cost per [qaly]{.smallcaps} gained is lower than the cost per [ly]{.smallcaps} gained. According to this model, and based on its assumptions, [tac]{.smallcaps} is a cost-effective treatment for adjuvant treatment of breast cancer. Results show that adjuvant [tac]{.smallcaps}---with secondary and primary prophylaxis---provides good economic value for women with node-positive breast cancer.

The major cost drivers of this model are the drug acquisition costs of [tac]{.smallcaps} and the proportion of patients who achieved [dfs]{.smallcaps}. In general, the sensitivity analyses indicated that the results were robust to change. Variations in chemotherapy costs, follow-up costs, supportive care costs, and utility values resulted in relatively similar incremental ratios for the cost per [ly]{.smallcaps} gained and the cost per [qaly]{.smallcaps} gained. Variations in rates of [dfs]{.smallcaps} had a significant effect on the incremental ratios---namely, poor [dfs]{.smallcaps} would result in a higher incremental ratio.

Our results were consistent with those from Au *et al.* [@b21-conc17-1-7], who reported a cost per [qaly]{.smallcaps} of \$18,505.54. They used Alberta provincial costs and also based their analyses on the [tac]{.smallcaps}--[fac]{.smallcaps} study. A similar study in the United Kingdom, with the same clinical trial data, also found that [tac]{.smallcaps} was more cost effective than [fac]{.smallcaps}. A model was also constructed around the data from the [bcirg]{.smallcaps} 001 trial to estimate the cost-effectiveness of [tac]{.smallcaps} compared with [fac]{.smallcaps} as adjuvant therapy for node-positive breast cancer. Parameters and sensitivity analyses were built around adverse events, cost of chemotherapy and support, survival estimates, utility weights, and costs of monitoring and care after relapse. The cost-effectiveness of [tac]{.smallcaps} compared with [fac]{.smallcaps} was £15,418/[ly]{.smallcaps} gained and £18,188/[qaly]{.smallcaps} gained. That study also looked at [g]{.smallcaps}-[csf]{.smallcaps} as primary prophylaxis and found an increase to £29,432/[qaly]{.smallcaps} gained. Although the [icer]{.smallcaps} was reported to be higher, the overall conclusions were similar to our own. The higher values may have resulted from the inclusion of additional adverse events such as anemia, pain, and vomiting. And because the analysis reflected the perspective of the U.K. National Health Service, differences in the cost of follow-up and community care may also have affected the [icer]{.smallcaps} [@b22-conc17-1-7].

Our study has a number of limitations. As used in the model, the clinical data from the [tac]{.smallcaps}--[fac]{.smallcaps} trial and the assumptions used when trial data were not available to estimate long-term costs may not be representative of real-life experience. Hormonal therapies were not included in the calculation of the cost-effectiveness because, per the [tac]{.smallcaps}-[fac]{.smallcaps} study, tamoxifen was administered on completion of chemotherapy to patients with estrogen or progesterone receptor--positive (or both) tumours. This treatment strategy would have been applied to both groups, and thus would have not affected the results for one therapy or the other.

The relative cost-effectiveness of [fec]{.smallcaps}-[d]{.smallcaps} (5-fluorouracil, epirubicin, cyclophosphamide, followed by docetaxel), a more commonly used regimen relative to [tac]{.smallcaps}, can be inferred from the results presented here and the 2008 cost-effectiveness analysis by Younis *et al.* [@b23-conc17-1-7], who compared the cost-effectiveness of [fec]{.smallcaps}-100 (5-fluorouracil, epirubicin, cyclophosphamide) with that of [fec]{.smallcaps}-[d]{.smallcaps} in women with node-positive breast cancer on adjuvant chemotherapy after surgical treatment. Their study reported an incremental cost difference of \$3,544 per patient and an [icur]{.smallcaps} of \$14,612/[qaly]{.smallcaps} gained [@b23-conc17-1-7]. They used a Markov model and reported the incremental cost utility over a 10-year horizon. Considering that the [tac]{.smallcaps} regimen has shown efficacy comparable to that of the [fec]{.smallcaps}-100 regimen, per the 5-year [dfs]{.smallcaps}s and [os]{.smallcaps}s observed in the [bcirg]{.smallcaps} 001 and [pacs]{.smallcaps} 01 studies, and that the [tac]{.smallcaps} regimen is, in general, more costly than the [fec]{.smallcaps}-100 regimen, the [fec]{.smallcaps}-[d]{.smallcaps} regimen could be expected to show a cost-effectiveness ratio comparable to the one reported by Younis *et al.* or even better when compared with the [tac]{.smallcaps} regimen.

6.. CONCLUSIONS
===============

Clinical results have shown that [tac]{.smallcaps} is superior to [fac]{.smallcaps} in terms of the primary efficacy endpoint of [dfs]{.smallcaps} and the secondary endpoint of [os]{.smallcaps}. The [tac]{.smallcaps} regimen offered improved response at a higher cost than that for [fac]{.smallcaps}. The incremental cost was \$6,921.24/[ly]{.smallcaps} gained and \$6,848.39/[qaly]{.smallcaps} gained for [tac]{.smallcaps} as compared with [fac]{.smallcaps} when secondary [g]{.smallcaps}-[csf]{.smallcaps} prophylaxis is given. These costs increase to \$13,183.26/[ly]{.smallcaps} gained and \$13,044.49/[qaly]{.smallcaps} gained when primary [g]{.smallcaps}-[csf]{.smallcaps} prophylaxis is given in the [tac]{.smallcaps} group. Overall, the cost-effectiveness ratios for [tac]{.smallcaps} compared with [fac]{.smallcaps} are low, indicating good economic value for the [tac]{.smallcaps} treatment in the adjuvant setting of node-positive breast cancer patients.
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![The model as a decision tree. pDeath... = probability of death from the indicated state \[No Relapse, Loc (locoregional) Relapse, distant Met (metastatic) Relapse\]; pRelapse = probability of relapse from the No Relapse state; pMetRelapse = probability of distant Met relapse from the Loc Relapse state; PercentMetRelapse = proportion of distant Met Relapse.](conc17-1-7f1){#f1-conc17-1-7}

###### 

Cost of drug treatment, chemotherapy regimens, supportive care, adverse events, diagnostic procedures, and follow-up procedures, Canadian dollars

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                                                     [tac]{.smallcaps}                                          [fac]{.smallcaps}                                                                                                      Source
  ------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Cost of drug treatment*                                                                                                                                                                                                                                                                       

   Drug acquisition (6 cycles)                                                                                 9,024.00                                                   301.92                                                                                                                 Cancer Care Ontario, 2006 [@b9-conc17-1-7]

   Chemotherapy administration (6 cycles)                                                                      1,522.08                                                   913.26                                                                                                                 Chair time: Cancer Care Ontario Drug Formulary\
                                                                                                                                                                                                                                                                                                 Nursing and overhead costs: 2002 costs[a](#tfn1-conc17-1-7){ref-type="table-fn"} (\$35/h and \$57.42/h respectively) inflated to 2006 using the Bank of Canada inflation calculator [@b11-conc17-1-7]

   TOTAL                                                                                                       10,546.08                                                  1,215.18                                                                                                               Drug acquisition plus chemotherapy administration

  *Chemotherapy regimens*                                                                                                                                                                                                                                                                        

   First-line                                                                                                  10,686--54,264[b](#tfn2-conc17-1-7){ref-type="table-fn"}   11,700--47,892[c](#tfn3-conc17-1-7){ref-type="table-fn"}   }                                                           Cancer Care Ontario, 2006 [@b9-conc17-1-7] (range for [her]{.smallcaps}2− to [her]{.smallcaps}2+)

   Second-line                                                                                                 3,300--10,686[d](#tfn4-conc17-1-7){ref-type="table-fn"}    3,300[e](#tfn5-conc17-1-7){ref-type="table-fn"}                                                                        

   Third-line                                                                                                  18,072[f](#tfn6-conc17-1-7){ref-type="table-fn"}           11,700[g](#tfn7-conc17-1-7){ref-type="table-fn"}                                                                       Cancer Care Ontario, 2006 [@b9-conc17-1-7] ([her]{.smallcaps}2+)

  *Supportive care cost components*                                                                                                                                                                                                                                                              

   Transfusion                                                                                                 41.60                                                      13.56                                                      }                                                           

   Ondansetron                                                                                                 31.50                                                      31.50                                                      Sunnybrook Health Sciences Centre, 2005 [@b12-conc17-1-7]   

   Dexamethasone                                                                                               6.00                                                       6.00                                                                                                                   

   TOTAL                                                                                                       79.10                                                      51.06                                                                                                                  Derived from the foregoing category costs and the proportion of patients receiving the therapies

   Average supportive care cost used in the model                                                              65.08                                                      65.08                                                                                                                  Average supportive care cost for the [tac]{.smallcaps} and [fac]{.smallcaps} arms

  *Cost of adverse events*                                                                                                                                                                                                                                                                       

   Febrile neutropenia                                                                                         2,367.23                                                   2,367.23                                                   }                                                           

   Stomatitis                                                                                                  3,151.18                                                   3,151.18                                                   Ontario Case Cost Initiative, 2005 [@b13-conc17-1-7]        

   Diarrheas                                                                                                   2,760.30                                                   2,760.30                                                   Bank of Canada inflation calculator [@b11-conc17-1-7]       

   Infections                                                                                                  2,367.30                                                   2,367.30                                                                                                               

   [g]{.smallcaps}-[csf]{.smallcaps} acquisition cost for secondary prevention of febrile neutropenia          1,239.77                                                   1,239.77                                                                                                               Sunnybrook Health Sciences Centre, 2005 [@b12-conc17-1-7]\
                                                                                                                                                                                                                                                                                                 Lalami *et al.,* 2004 [@b14-conc17-1-7]

  *Cost of diagnostic procedures performed at diagnosis*                                                                                                                                                                                                                                         

   TOTAL                                                                                                       643.04                                                     643.04                                                                                                                 Procedures from Will et al., 2000 [@b15-conc17-1-7]\
                                                                                                                                                                                                                                                                                                 Ontario Ministry of Health and Long-Term Care, 2004 [@b16-conc17-1-7] (validated by the clinical authors of this manuscript)

  *Total cost of laboratory tests*                                                                                                                                                                                                                                                               

   Total cost of all blood work                                                                                41.95                                                      41.95                                                                                                                  Ontario Ministry of Health and Long-Term Care, 2004 [@b16-conc17-1-7]

  *Follow-up costs*[h](#tfn8-conc17-1-7){ref-type="table-fn"}                                                                                                                                                                                                                                    

   Total average annual follow-up cost for years 1--3 for patients without breast cancer recurrence            582.82                                                     582.82                                                                                                                 Will *et al.,* 2000 [@b15-conc17-1-7] (\$467 non-inflated)\
                                                                                                                                                                                                                                                                                                 Bank of Canada inflation calculator [@b11-conc17-1-7] (inflated to \$582.82)

   Total average annual follow-up cost for years beyond year 3 for patients without breast cancer recurrence   356.93                                                     356.93                                                                                                                 Will *et al.,* 2000 [@b15-conc17-1-7] (\$286 non-inflated)\
                                                                                                                                                                                                                                                                                                 Bank of Canada inflation calculator [@b11-conc17-1-7] (inflated to \$356.93)

   Total average annual follow-up cost for patients with distant (metastatic) breast cancer                    1,729.10                                                   1,729.10                                                                                                               Costs and codes from Ontario Ministry of Health and Long-Term Care, 2004 [@b16-conc17-1-7] (procedure validated by the clinical authors of this manuscript)

   Total average annual follow-up cost for patients with locoregional breast cancer recurrence                 805.89                                                     805.89                                                                                                                 Will *et al.,* 2000 [@b15-conc17-1-7] (\$827 for years 1 and 2, \$612 for years 3 and 4, \$497 for years 5 and 6)\
                                                                                                                                                                                                                                                                                                 Bank of Canada inflation calculator [@b11-conc17-1-7] (inflated to \$1,032.76 for years 1 and 2, to \$764.27 for years 3 and 4, to \$620.65 for years 5 and 6)\
                                                                                                                                                                                                                                                                                                 Annual cost based on an average of 6 years
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Risebrough NA, Imrie K, Seung SJ, *et al.* An observational study of resource use and outcomes in indolent follicular non-Hodgkin's lymphoma for Canada. Unpublished data. 2002.

[her]{.smallcaps}2−: capecitabine or vinorelbine; [her]{.smallcaps}2+: trastuzumab plus vinorelbine.

[her]{.smallcaps}2−: docetaxel; [her]{.smallcaps}2+: trastuzumab plus docetaxel.

[her]{.smallcaps}2−: capecitabine or vinorelbine; [her]{.smallcaps}2+: capecitabine.

[her]{.smallcaps}2+: capecitabine.

[her]{.smallcaps}2+: docetaxel.

[her]{.smallcaps}2+: vinorelbine.

Follow-up care includes physician assessments, clinic costs (including overhead), hematology, biochemistry, bone scan, chest radiography, liver ultrasonography, and annual mammogram [@b15-conc17-1-7].

[tac]{.smallcaps} = docetaxel, doxorubicin, cyclophosphamide; [fac]{.smallcaps} = 5-fluorouracil, doxorubicin, cyclophosphamide; [her]{.smallcaps}2− = disease negative for the human epidermal growth factor receptor; [her]{.smallcaps}2+ = disease positive for the human epidermal growth factor receptor.

###### 

Percentage of grades 3 and 4 adverse events [@b1-conc17-1-7]

  Regimen             Treated population (*n*)   Adverse events (%)                 
  ------------------- -------------------------- -------------------- ------ ------ ------
  [tac]{.smallcaps}   744                        24.7                 7.10   3.80   3.90
  [fac]{.smallcaps}   736                        2.50                 2.00   1.80   2.20

Extracted from Martin *et al.,* 2005, Table 3, p. 2310 [@b1-conc17-1-7].

Non-hematologic infections.

[tac]{.smallcaps} = docetaxel, doxorubicin, cyclophosphamide; [fac]{.smallcaps} = 5-fluorouracil, doxorubicin, cyclophosphamide.

###### 

Secondary granulocyte colony--stimulating factor ([g]{.smallcaps}-[csf]{.smallcaps}) prophylaxis[a](#tfn13-conc17-1-7){ref-type="table-fn"}

                                                              [tac]{.smallcaps}   [fac]{.smallcaps}
  ----------------------------------------------------------- ------------------- -------------------
  Treated population (*n*)                                    744                 736
  Patients receiving prophylaxis \[*n* (%)\]                  217 (29.17)         41 (5.57)
  Cycles with prophylaxis \[*n* (%)\]                         799 (18.7)          126 (2.9)
  Average cycles under prophylaxis (*N*/*n*)                  3.7 (799/217)       3.1 (126/41)
  Average prophylaxis administrations per patient (*N*/*n*)   1.07 (799/744)      0.17 (126/736)

From Aventis Pharma Research and Development, 2004, Table 78, p. 193 [@b3-conc17-1-7].

[tac]{.smallcaps} = docetaxel, doxorubicin, cyclophosphamide; [fac]{.smallcaps} = 5-fluorouracil, doxorubicin, cyclophosphamide.

###### 

Incremental cost-effectiveness ratio ([icer]{.smallcaps}) and incremental cost--utility ratio ([icur]{.smallcaps}) summary table, Canadian dollars

  Variable and variations                                                    [icer]{.smallcaps} (CA\$)   [icur]{.smallcaps} (CA\$)
  -------------------------------------------------------------------------- --------------------------- ---------------------------
  Base case                                                                  6,921.24                    6,848.39
  Adverse event rates ([geicam]{.smallcaps} study [@b19-conc17-1-7])         6,893.22                    6,820.66
  Adverse event rates                                                                                    
   Rates increased by 25%                                                    7,129.14                    7,054.09
   Rates decreased by 25%                                                    6,713.35                    6,642.68
   Rates in [tac]{.smallcaps} increased by 25%                               7,188.70                    7,113.03
   Rates in [tac]{.smallcaps} decreased by 25%                               6,653.78                    6,583.74
   Rates of febrile neutropenia increased by 25%                             7,076.75                    7,002.26
   Rates of febrile neutropenia in decreased by 25%                          6,765.74                    6,694.52
  Relapse rate                                                                                           
   Increased probability of relapse by 25% in [tac]{.smallcaps} arm          21,126.10                   21,126.10
   Decreased probability of relapse by 25% in [tac]{.smallcaps} arm          2,715.32                    2,661.37
  Follow-up cost                                                                                         
   No recurrence + 25% metastatic − 25%                                      7,148.54                    7,073.29
   No recurrence − 25% metastatic + 25%                                      6,693.94                    6,623.48
  Ratio of recurrence                                                                                    
   Recurrence at 25%                                                         7,203.09                    7,127.26
   Recurrence at 100%                                                        6,357.56                    6,290.63
  Utility                                                                                                
   Equate utility value                                                      6,921.24                    6,777.05
   Lowest utility value                                                      6,921.24                    7,393.15
   Highest utility value                                                     6,921.24                    6,571.69
  Bootstrapping                                                                                          
   Best case                                                                 3,132.16                    3,060.59
   Worst case                                                                20,370.59                   20,036.64
  Primary prophylaxis ([g]{.smallcaps}-[csf]{.smallcaps})                    13,183.26                   13,044.49
  Adverse event rates ([geicam]{.smallcaps} study rates [@b19-conc17-1-7])                               
   Rates increased by 25%                                                    13,277.28                   13,137.52
   Rates decreased by 25%                                                    13,089.32                   12,951.54
   Rates in [tac]{.smallcaps} increased by 25%                               13,355.05                   13,214.47
   Rates in [tac]{.smallcaps} decreased by 25%                               13,011.47                   12,874.51
   Rates of febrile neutropenia increased by 25%                             13,265.49                   13,125.86
   Rates of febrile neutropenia decreased by 25%                             13,101.03                   12,963.12
  Relapse rate                                                                                           
   Increased probability of relapse by 25% in [tac]{.smallcaps} arm          37,736.72                   37,736.72
   Decreased probability of relapse by 25% in [tac]{.smallcaps} arm          6,581.31                    6,411.48

[tac]{.smallcaps} = docetaxel, doxorubicin, cyclophosphamide; [g]{.smallcaps}-[csf]{.smallcaps} = granulocyte colony--stimulating factor.

###### 

Percentage of grades 3 and 4 adverse events[a](#tfn16-conc17-1-7){ref-type="table-fn"}

  Adverse events                                                                                       [tac]{.smallcaps}[b](#tfn17-conc17-1-7){ref-type="table-fn"} \[% (*n* evaluable pts)\]   [fac]{.smallcaps}[c](#tfn18-conc17-1-7){ref-type="table-fn"}   
  ---------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- -------------------------------------------------------------- ------------
  Febrile neutropenia (per protocol, in 1 or more cycles)[d](#tfn19-conc17-1-7){ref-type="table-fn"}   24.6 (114)                                                                               6.50 (519)                                                     2.30 (519)
  Mucositis and stomatitis [@b20-conc17-1-7],[e](#tfn20-conc17-1-7){ref-type="table-fn"}               6.40 (109)                                                                               2.60 (111)                                                     2.70 (111)
  Diarrhea [@b19-conc17-1-7],[f](#tfn21-conc17-1-7){ref-type="table-fn"}                               7.00 (114)                                                                               2.60 (519)                                                     0.80 (519)
  Infections [@b19-conc17-1-7],[f](#tfn21-conc17-1-7){ref-type="table-fn"}                             2.80 (109)                                                                               1.70 (111)                                                     1.80 (111)

From Martin *et al.,* 2006, Table 3 [@b17-conc17-1-7].

Rates without (Pre) and with (Post) primary granulocyte colony--stimulating factor prophylaxis.

Rates with granulocyte colony--stimulating factor given as secondary prophylaxis.

Protocol definition implies a fever of 38.1°C or higher, with grade 4 neutropenia requiring intravenous antibiotics or hospitalization (or both), in the same cycle.

Based on 448 randomized subjects in total (p. 65, Table 14 [@b17-conc17-1-7]).

Grades 3 and 4 toxicity, with more final results. Only grades 2--4 diarrhea were reported earlier.

[tac]{.smallcaps} = docetaxel, doxorubicin, cyclophosphamide; pts = patients; [fac]{.smallcaps} = 5-fluorouracil, doxorubicin, cyclophosphamide.
